JNNP:抑郁症患者REM睡眠行为障碍的患病率及其相关因素

2021-11-14 MedSci原创 MedSci原创

影响全球近3亿人的抑郁症已成为全球第三大致残原因。有人认为,“晚发性”抑郁症更可能与神经退行性变的未来风险相关。需要一种更具体的特征或/和生物标记物来识别和治疗这种神经退行性变

影响全球近3亿人的抑郁症已成为全球第三大致残原因。有人认为,“晚发性”抑郁症更可能与神经退行性变的未来风险相关。需要一种更具体的特征或/和生物标记物来识别和治疗这种神经退行性变相关抑郁症亚型。快速眼动(REM)睡眠行为障碍(RBD)是一种新型的嗜睡障碍,其特征是反复的做梦行为导致重复的睡眠相关发声/运动行为和睡眠相关损伤(SRI),并伴有REM睡眠中的肌肉张力丧失。

90%以上的特发性RBD(iRBD)患者会发展为α-突触核蛋白病神经退行性变,其中大多数是帕金森病(PD)和路易体痴呆(DLB)。RBD在普通人群中的患病率约为1%。RBD特征出现在精神病人群中,尤其是重度抑郁症(MDD)患者。通过使用最近1年的SRI史作为RBD症状的替代项目,之前估计精神科门诊患者RBD的终生患病率为5.8%(MDD亚组为6.8%)。然而,vPSG在MDD患者(MDD+RBD)中证实RBD的真实患病率可能被低估。通过验证筛查问卷和vPSG确认,本研究进行了这项两阶段研究,以(1)确定MDD+RBD的患病率;(2)研究MDD+RBD患者的临床相关性,尤其是神经退行性变的风险。本文发表在《神经病学,神经外科学和精神病学杂志》上()。

香港RBD问卷(RBDQ-HK)是一份包含13个项目的问卷,包含终生和最近1年的子量表,涵盖RBD中的梦相关因素和行为因素。先前的验证研究表明,诊断精神病患者RBD的临界值为20/21。共有302名患者同意进行进一步的临床评估,其中,精神病诊断通过DSM-IV轴I疾病的结构化临床访谈确定。抑郁症的严重程度和非典型症状使用汉密尔顿抑郁评定量表(SIGH-ADS)的结构化访谈威廉亚洲博彩公司 进行评估由经验丰富的精神病医生进行。患者还完成了与睡眠、生活方式因素和接触史(如头部受伤)相关的额外问卷调查。相关的医疗信息是在一个完善的电子医疗数据库中获得的。

研究流程图 

筛查阳性(RBDQ-HK>20)患者以及随机选择的部分筛查阴性患者被邀请参加睡眠实验室vPSG评估的第2阶段研究。根据美国睡眠医学学会标准(2012年)对睡眠阶段、呼吸事件、觉醒和运动事件进行评分在RSWA的允许下,13名患者被要求在研究期间继续他们的常规药物治疗。如果出现显著的呼吸暂停/低通气事件(呼吸暂停低通气指数≥15) ,患者将被邀请进行第二晚vPSG,滴定持续气道正压,第二晚vPSG数据将用于评分。REM睡眠时下巴肌肉上的肌电图(EMG)活动水平用于确定RSWA的严重程度,因为建议下巴肌电图提供最高的阶段性EMG活动。

在不同领域测量与RBD和神经退行性变相关的危险因素和前驱标记物。使用帕金森病自主神经功能障碍(SCOPA-AUT)量表中的结果量表测量自主神经功能障碍症状,并在仰卧位站立2分钟内(休息5分钟后)进一步测量立位血压变化。采用最新的运动障碍学会(MDS)研究标准来估计前驱症状PD的总似然比(LR)和概率。RBD的诊断是根据国际睡眠障碍分类第三版标准进行的。在睡眠医学方面经验丰富的精神科医生通过对睡眠模式和障碍23的诊断性访谈和病例注释审查,澄清了RBD反复出现的做梦行为症状。

第一阶段,接触了751名抑郁症患者,其中504名(平均年龄49.85岁,77.0%为女性,应答率67.1%)同意本研究。在诊断访谈和医疗记录审查后,48名患者因发作性睡病(n=1)、中风(n=1)、创伤后应激障碍(n=16)、药物滥用(n=11)、双相情感障碍(n=17)和终身未诊断MDD(n=2)而被排除在外。一名患者因未完成RBDQ-HK而被排除在外。其余455名符合条件的MDD患者(中位年龄(IQR)=52.66(15.35)岁,77.58%为女性)被确定为全筛查样本。其中302名患者(54.04(13.12)岁,76.49%为女性)完成了额外的问卷调查和临床访谈,并被视为样本总数。

伴和不伴RBD的重度抑郁症患者的对数总似然比(LR)

筛查阳性患者包括更多的吸烟者(14.39%比7.36%),更有可能报告头部损伤史(12.23%比6.13%),但在调整人口统计学后,差异变得不显著。筛查阳性患者也表现出更严重的抑郁症状(汉密尔顿抑郁评分量表17项评分),比其对应患者更非典型的抑郁特征(4.00(4.00)vs 3.00(4.00))。此外,筛查阳性患者白天嗜睡率较高,失眠率可能较高。共有81名患者(54.08(12.40)岁,65.43%为女性,51名筛查阳性)完成了vPSG和神经认知评估。8名男性和4名女性筛查阳性MDD患者(即MDD+RBD,RBD发病年龄=53(11)岁,3名患者在开始服用抗抑郁药之前报告RBD发病)证实RBD,其余69名患者被归类为非RBD。MDD+RBD的加权患病率为8.77%。MDD+RBD与色觉和嗅觉缺陷以及PD的高度相关。

总之,在精神科门诊部,几乎9%的MDD患者有vPSG证实的RBD。共病MDD+RBD可能是MDD的一个亚型,伴有潜在的α-突触核蛋白病神经退行性变。应强调RBD症状的系统筛查和vPSG确认的必要性,以识别这种MDD亚型,从而加强个性化治疗和未来的神经保护,以防止神经退行性变。

Wang JChau SWHLam SP, et al Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder: a two-phase study

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988620, encodeId=940d198862025, content=<a href='/topic/show?id=1fe2549e72e' target=_blank style='color:#2F92EE;'>#抑郁症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54977, encryptionId=1fe2549e72e, topicName=抑郁症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Sat Feb 19 01:39:37 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709779, encodeId=442f1e09779a5, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Mon Sep 26 23:39:37 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250772, encodeId=d2f01250e72b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457546, encodeId=4101145e5466b, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Tue Feb 01 01:39:37 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988620, encodeId=940d198862025, content=<a href='/topic/show?id=1fe2549e72e' target=_blank style='color:#2F92EE;'>#抑郁症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54977, encryptionId=1fe2549e72e, topicName=抑郁症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Sat Feb 19 01:39:37 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709779, encodeId=442f1e09779a5, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Mon Sep 26 23:39:37 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250772, encodeId=d2f01250e72b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457546, encodeId=4101145e5466b, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Tue Feb 01 01:39:37 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988620, encodeId=940d198862025, content=<a href='/topic/show?id=1fe2549e72e' target=_blank style='color:#2F92EE;'>#抑郁症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54977, encryptionId=1fe2549e72e, topicName=抑郁症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Sat Feb 19 01:39:37 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709779, encodeId=442f1e09779a5, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Mon Sep 26 23:39:37 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250772, encodeId=d2f01250e72b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457546, encodeId=4101145e5466b, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Tue Feb 01 01:39:37 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1988620, encodeId=940d198862025, content=<a href='/topic/show?id=1fe2549e72e' target=_blank style='color:#2F92EE;'>#抑郁症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54977, encryptionId=1fe2549e72e, topicName=抑郁症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Sat Feb 19 01:39:37 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709779, encodeId=442f1e09779a5, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Mon Sep 26 23:39:37 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250772, encodeId=d2f01250e72b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457546, encodeId=4101145e5466b, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Tue Feb 01 01:39:37 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1988620, encodeId=940d198862025, content=<a href='/topic/show?id=1fe2549e72e' target=_blank style='color:#2F92EE;'>#抑郁症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54977, encryptionId=1fe2549e72e, topicName=抑郁症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Sat Feb 19 01:39:37 CST 2022, time=2022-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709779, encodeId=442f1e09779a5, content=<a href='/topic/show?id=3c0e90045ac' target=_blank style='color:#2F92EE;'>#行为障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90045, encryptionId=3c0e90045ac, topicName=行为障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=895a31785550, createdName=12498cb5m23暂无昵称, createdTime=Mon Sep 26 23:39:37 CST 2022, time=2022-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250772, encodeId=d2f01250e72b8, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457546, encodeId=4101145e5466b, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Mon Nov 15 13:39:37 CST 2021, time=2021-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752311, encodeId=a8371e5231189, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15303, encryptionId=28a915303ec, topicName=REM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78bc36479935, createdName=tongyongming, createdTime=Tue Feb 01 01:39:37 CST 2022, time=2022-02-01, status=1, ipAttribution=)]
    2022-02-01 tongyongming

相关威廉亚洲官网

Lancet:COVID-19导致的全球抑郁症和焦虑症的流行率和负担分析

精神障碍是造成全球健康相关负担的主要原因,其中抑郁症和焦虑症是造成这一负担的主要因素。

Nature Neuroscience:重大发现,抑郁症是与生俱来的

抑郁症(MDD),是一种常见的精神障碍,主要表现为情绪低落、兴趣减低、思维迟缓、饮食和睡眠差等症状,抑郁症患者与心血管疾病、糖尿病和阿尔茨海默病发病率的增加有关,死亡率也较高。迄今,并不清楚抑郁症的病

Age & Ageing:注意啦!老年人髋部骨折后抑郁风险明显增加!

髋部骨折后的老年人有独特的抑郁症状亚型,并提供了独特临床表型的确认证据

Nat Med:全球首例!脑电刺激成功拯救重度抑郁症患者,治愈抑郁症时代离williamhill asia 不远了?

最近,美国加州大学旧金山分校的研究团队在《Nature Medicine》上发表了一项研究,为治疗抑郁症提供了新的解决思路。

Lancet:全球抑郁症发病率大幅上升,女性是男性的2倍

2021年10月8日,美国华盛顿大学和澳大利亚昆士兰大学的研究人员在《柳叶刀》期刊上发表了题为:Global prevalence and burden of depressive and anxie

J Renal Nutr:老年慢性肾病患者总是情绪低落,查查这两种血液标志物水平!

血清LDL胆固醇水平和ARA/LA比值与CKD患者抑郁症状的严重程度相关,因此这些指标可用于预测这些患者的预后,而不受任何因果关系的影响。

拓展阅读

The British Journal of Psychiatry:致幻剂辅助治疗焦虑症患者的长期随访研究

LSD辅助治疗在减少焦虑和抑郁症状方面具有显著且持久的效果,且没有报告显著的不良事件或闪回现象,表明其在长期内的安全性。

改善神经炎症,美丽金丝桃成分开启抗抑郁新篇章

文章旨在阐明HJ可通过靶向腺苷激酶(ADK)从而抑制小胶质细胞P2X7R/TLR4通路介导的神经炎症来治疗抑郁症。

Translational Psychiatry:基于机器学习和深度学习方法对抑郁症相关血液DNA甲基化的全面多队列探索

本研究发现1987个与抑郁症相关的CpG位点,随机森林模型在批次处理的数据中表现最佳,AUC达0.76,而在特征预选的模型中,AUC最高达到0.91,显示了机器学习在抑郁症DNA甲基化分析中的潜力。

Translational Psychiatry:跨诊断视角下tDCS对抑郁和焦虑症状的影响评估:随机对照试验的系统综述和Meta分析

tDCS显著改善了抑郁症状,对焦虑症状也表现出一定的疗效,尤其在左背外侧前额叶皮层(DLPFC)的刺激效果显著。这一发现支持了tDCS作为一种跨诊断的干预措施,在临床上具有广泛的应用潜力。

Translational Psychiatry:甲基丙二酸与抑郁症状及死亡率的关联

甲基丙二酸(MMA)水平升高与抑郁症状和较高的死亡风险有关,且这种关联在男性和60岁以上人群中更为显著。然而,抑郁症状并未在MMA和死亡率之间起中介作用。

难治性抑郁症的最新研究进展。一文汇总近年研究

介绍难治性抑郁症的定义和诱导因素,阐述其治疗方案最新进展,包括电抽搐疗法、新药物、联合疗法等,展望未来治疗前景。